Document Detail


Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
MedLine Citation:
PMID:  10028046     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The cytochrome P450 (CYP) superfamily of enzymes are catalytically competent toward an unusually diverse array of lipophilic chemicals. The major microsomal CYP in human liver, CYP3A4, participates in the oxidative biotransformation of most drugs. Accordingly, it is not surprising that CYP activity is also readily inhibited by many drugs. Such interactions may elicit adverse toxic effects in patients and this situation is exacerbated by the practise of polypharmacy. Clinical studies have suggested that the judicious selection of drugs for combination therapy may be a relatively simple means by which drug interactions can be avoided. Such studies will rely heavily on basic information obtained from biochemical studies that describe the substrate preferences of CYPs and molecular studies on the factors that determine CYP levels in subjects. This review focuses on the information that is emerging on CYP substrate and inhibitor specificity, protein structure from homology modelling approaches and CYP expression in liver as it emerges from molecular analyses. With information of this type, drawn from several different sources, it will eventually be possible to reconcile the likelihood of drug interactions produced by specific combinations of drugs and predict those individuals who are at risk from such interactions, as a consequence of their genetic makeup.
Authors:
M Murray
Related Documents :
16248836 - Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
11523726 - Drug interactions with irbesartan.
12649386 - Suppression of hepatic cyp3a1/2 and cyp2c11 by cyclosporine is not mediated by altering...
15637526 - Clinical consequences of cytochrome p450 2c9 polymorphisms.
25475096 - Interactions between herbs and antidiabetics: an overview of the mechanisms, evidence, ...
2335796 - Medication and the work environment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  International journal of molecular medicine     Volume:  3     ISSN:  1107-3756     ISO Abbreviation:  Int. J. Mol. Med.     Publication Date:  1999 Mar 
Date Detail:
Created Date:  2000-10-13     Completed Date:  2000-10-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9810955     Medline TA:  Int J Mol Med     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  227-38     Citation Subset:  IM    
Affiliation:
School of Physiology and Pharmacology, University of New South Wales, Sydney, NSW 2052, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cytochrome P-450 Enzyme System / antagonists & inhibitors*,  chemistry,  classification,  metabolism*
Drug Interactions
Drug Therapy, Combination
Enzyme Inhibitors / adverse effects,  chemistry,  metabolism,  pharmacology*
Humans
Liver / enzymology,  metabolism
Pharmaceutical Preparations / chemistry,  metabolism*
Protein Conformation
Substrate Specificity
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Pharmaceutical Preparations; 9035-51-2/Cytochrome P-450 Enzyme System

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcomes of swallowing rehabilitation in chronic brainstem dysphagia: A retrospective evaluation.
Next Document:  The role of CD5-expressing B cells in health and disease (review).